The phase II single-arm REDUCTOR trial assessed the feasibility of cytoreduction with neoadjuvant BRAF/MEK-inhibitor to facilitate surgical resection of locally advanced, unresectable BRAF-mutant melanoma. The gene discussed is BRAF; the disease is melanoma.